UY35890A - Uso de laquinimod para retrasar la progresión de la enfermedad de huntington - Google Patents
Uso de laquinimod para retrasar la progresión de la enfermedad de huntingtonInfo
- Publication number
- UY35890A UY35890A UY0001035890A UY35890A UY35890A UY 35890 A UY35890 A UY 35890A UY 0001035890 A UY0001035890 A UY 0001035890A UY 35890 A UY35890 A UY 35890A UY 35890 A UY35890 A UY 35890A
- Authority
- UY
- Uruguay
- Prior art keywords
- laquinimod
- disease
- progression
- huntington
- delay
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D1/00—Containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material, by deep-drawing operations performed on sheet material
- B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
- B65D1/0207—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by material, e.g. composition, physical features
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/264—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Métodos para tratar o retrasar la progresión de la enfermedad en un sujeto afectado por la enfermedad de Huntington (HD) que comprende administrar al sujeto entre 0,5 y 1,5 mg/día laquinimod. La presente invención también provee envases, envases terapéuticos y composiciones farmacéuticas,que comprenden una o más dosis unitarias de entre 0,5 y 1,5 mg de laquinimod para tratar o retrasar la progresión de la enfermedad en un sujeto afectado por HD. También se divulga el uso del laquinimod en la fabricación de un medicamento que comprende una o más dosis unitarias de entre 0,5 y 1,5 mg de laquinimod para usar para tratar o retrasar la progresión de la enfermedad en un sujeto afectado por HD.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361919604P | 2013-12-20 | 2013-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35890A true UY35890A (es) | 2015-07-31 |
Family
ID=53398901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035890A UY35890A (es) | 2013-12-20 | 2014-12-18 | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington |
Country Status (14)
Country | Link |
---|---|
US (7) | US20150174118A1 (es) |
EP (1) | EP3082814A4 (es) |
KR (1) | KR20160110395A (es) |
AR (1) | AR098832A1 (es) |
AU (1) | AU2014364447A1 (es) |
BR (1) | BR112016014507A2 (es) |
CA (1) | CA2933380A1 (es) |
EA (1) | EA201691299A1 (es) |
HK (1) | HK1225972A1 (es) |
IL (1) | IL246077A0 (es) |
MX (1) | MX2016008027A (es) |
TW (1) | TW201609098A (es) |
UY (1) | UY35890A (es) |
WO (1) | WO2015095548A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220070057A (ko) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
EP3532154B1 (en) | 2016-10-28 | 2023-08-23 | Medtronic, Inc. | Autotitration of therapy using detected electrical activity |
EP3570841A4 (en) * | 2017-01-18 | 2020-08-19 | Coherus Biosciences, Inc. | PPARY AGONIST FOR TREATMENT OF HUNTINGTON'S DISEASE |
MX2019011867A (es) | 2017-04-03 | 2020-01-09 | Coherus Biosciences Inc | Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva. |
KR20210003715A (ko) * | 2018-04-23 | 2021-01-12 | 시우-롱 리 | 헌팅턴병을 치료하기 위한 진세노사이드 m1의 용도 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2035001T3 (da) * | 2006-06-12 | 2012-02-27 | Teva Pharma | Stabile laquinimod-tilberedninger |
ME02495B (me) * | 2009-08-10 | 2017-02-20 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
JP2013544887A (ja) * | 2010-12-07 | 2013-12-19 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド(laquinimod)の使用 |
US8889627B2 (en) * | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
TW201410243A (zh) * | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型1(cb1)媒介之疾病之拉喹莫德(laquinimod) |
AU2013323131A1 (en) * | 2012-09-27 | 2015-05-07 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
US20140107154A1 (en) * | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
-
2014
- 2014-12-18 EP EP14871229.2A patent/EP3082814A4/en not_active Withdrawn
- 2014-12-18 WO PCT/US2014/071205 patent/WO2015095548A1/en active Application Filing
- 2014-12-18 AR ARP140104762A patent/AR098832A1/es unknown
- 2014-12-18 EA EA201691299A patent/EA201691299A1/ru unknown
- 2014-12-18 US US14/575,357 patent/US20150174118A1/en not_active Abandoned
- 2014-12-18 BR BR112016014507A patent/BR112016014507A2/pt active Search and Examination
- 2014-12-18 CA CA2933380A patent/CA2933380A1/en not_active Abandoned
- 2014-12-18 TW TW103144386A patent/TW201609098A/zh unknown
- 2014-12-18 UY UY0001035890A patent/UY35890A/es not_active Application Discontinuation
- 2014-12-18 MX MX2016008027A patent/MX2016008027A/es unknown
- 2014-12-18 AU AU2014364447A patent/AU2014364447A1/en not_active Abandoned
- 2014-12-18 KR KR1020167019861A patent/KR20160110395A/ko not_active Application Discontinuation
-
2016
- 2016-06-07 IL IL246077A patent/IL246077A0/en unknown
- 2016-12-16 HK HK16114337A patent/HK1225972A1/zh unknown
- 2016-12-22 US US15/388,947 patent/US20170100388A1/en not_active Abandoned
-
2017
- 2017-04-05 US US15/479,435 patent/US20170209427A1/en not_active Abandoned
- 2017-07-18 US US15/653,132 patent/US20170312264A1/en not_active Abandoned
- 2017-10-26 US US15/794,846 patent/US20180042913A1/en not_active Abandoned
-
2018
- 2018-03-09 US US15/916,375 patent/US20180193328A1/en not_active Abandoned
- 2018-07-05 US US16/028,224 patent/US20180311230A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3082814A1 (en) | 2016-10-26 |
MX2016008027A (es) | 2016-10-12 |
HK1225972A1 (zh) | 2017-09-22 |
IL246077A0 (en) | 2016-07-31 |
EP3082814A4 (en) | 2017-06-21 |
TW201609098A (zh) | 2016-03-16 |
US20150174118A1 (en) | 2015-06-25 |
US20170312264A1 (en) | 2017-11-02 |
US20170100388A1 (en) | 2017-04-13 |
AR098832A1 (es) | 2016-06-15 |
AU2014364447A1 (en) | 2016-08-04 |
EA201691299A1 (ru) | 2016-12-30 |
KR20160110395A (ko) | 2016-09-21 |
US20180042913A1 (en) | 2018-02-15 |
CA2933380A1 (en) | 2015-06-25 |
US20180193328A1 (en) | 2018-07-12 |
BR112016014507A2 (pt) | 2018-05-22 |
WO2015095548A1 (en) | 2015-06-25 |
US20180311230A1 (en) | 2018-11-01 |
US20170209427A1 (en) | 2017-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2017000105A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
CO7141411A2 (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas | |
CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
MX2021002321A (es) | Nuevos metodos. | |
MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
AR091706A1 (es) | Formulaciones de laquinimod sin agentes alcalinizantes | |
AR100369A1 (es) | Composición de dosis fija de formoterol y budesonide | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
CL2016001843A1 (es) | Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero. | |
ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211221 |